Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders

References

• Cohen JM, Cooper N, Chakrabarti S et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007; 48(2): 256–269.
   PubMed Web of Science ®Google Scholar
• Rickinson AB, Lee SP, Steven NM. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 1996; 8(4): 492–497.
   PubMed Web of Science ®Google Scholar
• van Esser JW, van der Holt B, Meijer E et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lympho-proliferative disease following T-cell-depleted SCT. Blood 2001; 98(4): 972–978.
   PubMed Web of Science ®Google Scholar
• Meij P, van Esser JW, Niesters HG et al. Impaired recovery of Epstein-Barr virus (EBV) specific CD8± T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101(11): 4290–4297.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Milligan DW, Pillay D et al. Reconstitution of theEpstein-Barr virus-specific cytotoxic T-lymphocyte response fol-lowing T-cell-depleted myeloablative and nonmyeloablative allo-geneic stem cell transplantation. Blood 2003; 102(3):839–842.
   PubMed Web of Science ®Google Scholar
• Juvonen E, Aalto S, Tarkkanen J et al. Retrospective evaluation ofserum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. Haematologica 2007; 92(6): 819–825.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Weisdorf DJ, DeFor T et al. Marked increased riskof Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108(8): 2874–2880.
   PubMed Web of Science ®Google Scholar
• Juvonen E, Aalto SM, Tarkkanen J et al. High incidence of PTLDafter non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32(1): 97–102.
   PubMed Web of Science ®Google Scholar
• Buyck HC, Ball S, Junagade P, Marsh J, Chakrabarti S. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following Allo-SCT for acquired aplastic anemia. Bone Marrow Transplant 2009; 43(10): 813–816.
   PubMed Web of Science ®Google Scholar
• Marsh JC, Ball SE, Cavenagh J et al. British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2009; 147(1): 43–70.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15(6): 825–828.
   PubMed Web of Science ®Google Scholar
• Lee Si, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9(4): 215–233.
   PubMed Web of Science ®Google Scholar
• Smith JM, Corey L, Healey Pi, Davis CL, McDonald RA. Adolescents are more likely to develop posttransplant lymphopro-liferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation 2007; 83(11): 1423–1428.
   PubMed Web of Science ®Google Scholar
• Paya CV, Fung JJ, Nalesnik MA et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68(10): 1517–1525.
   PubMed Web of Science ®Google Scholar
• Stevens Si, Verkuijlen SA, Brule Ai, Middeldorp JM. Comparison of quantitative competitive PCR with LightCycler-based PCR for measuring Epstein-Barr virus DNA loads in clinical specimens. J Clin Microbiol 2002; 40(11): 3986–3992.
   PubMed Web of Science ®Google Scholar
• Falcao RP, Voltarelli JC, Bottura C. Some immunological studies in aplastic anemia. J Clin Lab Immunol 1983; 10(1): 25–28.
   PubMedGoogle Scholar
• Falcao RP, Voltarelli JC, Bottura C. T-cell subsets in patients with aplastic anemia. Braz J Med Biol Res 1984; 17(2): 151–156.
   PubMed Web of Science ®Google Scholar
• Islam MS, Anoop P, Rice P et al. Early cytomegalovirus infections following allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders. Hematology, 2010; 15(1): 4–10.
   PubMed Web of Science ®Google Scholar
• Meijer E, Cornelissen JJ. Epstein-Barr virus-associated lym-phoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008; 15(6): 576–585.
   PubMed Web of Science ®Google Scholar
• Meerbach A, Wutzler P, Hafer R, Zintl F, Gruhn B. Monitoring of Epstein-Barr virus load after haematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 2008; 80(3): 441–454.
   PubMed Web of Science ®Google Scholar
• Meijer E, Spijkers S, Moschatsis S et al. Active Epstein-Barr virus infection after allogeneic stem cell transplantation: re-infection or reactivation? Transpl Infect Dis 2005; 7(1): 4–10.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Fischer SH, Li L et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007; 109(8): 3219–3224.
   PubMed Web of Science ®Google Scholar
• Ocheni S, Kroeger N, Zabelina T et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008; 42(3): 181–186.
   PubMed Web of Science ®Google Scholar
• Gupta V, Ball SE, Yi QL et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004; 10(12): 867–876.
   PubMed Web of Science ®Google Scholar
• Islam MS, Anoop P, Datta-Nemdharry P et al. Implications of CD34± cell dose on clinical and haematological outcome of allogeneic stem cell transplantation for acquired aplastic anaemia. Bone Marrow Transplant 2010; 45(5): 886–894.
   PubMed Web of Science ®Google Scholar
• Marshall NA, Howe JG, Formica R et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000; 96(8): 2814–2821.
   PubMed Web of Science ®Google Scholar